Colicchia, A. and Fabian, D. and Grabenhofer, L. and Geiger-Gritsch, S. and Grössmann-Waniek, N. and Malikova, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Teprotumumab (TEPEZZA®) for moderate-to-severe thyroid eye disease. Decision Support Document for the Austrian Appraisal Board 003.

Colicchia, A. and Fabian, D. and Grabenhofer, L. and Grössmann-Waniek, N. and Malíková, E. and Rothschedl, E. and Sehic, O. and Wild, C. and Wolf, S. and Zechmeister-Koss, I. (2025): Fidanacogene elaparvovec (BEQVEZ®) for the treatment of moderately severe to severe haemophilia B. Decision Support Document for the Austrian Appraisal Board 002.

Grössmann-Waniek, N. and Wild, C. and Malíková, E. and Wolf, S. and Fabian, D. and Sehic, O. and Zechmeister-Koss, I. (2025): Exagamglogene autotemcel (Exa-cel, Casgevy®) for the treatment of beta-thalassaemia and severe sickle cell disease. Decision Support Document for the Austrian Appraisal Board 001.